Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board

LOS ANGELES, July 5, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced Laszlo Radvanyi, Ph.D., an Associate Professor in the Department of Melanoma Medical Oncology Research at the University of Texas MD Anderson Cancer Center in Houston, has joined its Scientific and Medical Advisory Board.  MD Anderson is one of the world's premier cancer centers, conducting advanced research and education programs and providing patient care.

"Dr. Radvanyi's research using tumor-infiltrating lymphocytes (TILs) for the treatment of Stage IV metastatic melanoma, including ongoing Phase I and Phase II clinical trials, complements the development of our product candidate Contego™ for the treatment of Stage IV metastatic melanoma," stated Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma.  "Dr. Radvanyi's knowledge and expertise in growing TILs ex vivo will be helpful as we scale-up the manufacture of Contego in anticipation of the commencement of clinical trials for Contego."

Dr. Radvanyi received his Ph.D. in clinical biochemistry from the University of Toronto.  His main research area is tumor immunology studying immune regulation in cancer and identifying new antigens as targets for anti-cancer T-cell therapy.  After completing postdoctoral work in Toronto and at Harvard University in Boston at the Joslin Diabetes Center, Dr. Radvanyi joined the Immunology Group at Sanofi-Pasteur in Toronto in 2000 as a Senior Scientist where he helped lead an antigen discovery program that led to the discovery of a group of over-expressed breast cancer-specific genes that are candidates for antigen-specific vaccines against breast cancer. In 2005, Dr. Radvanyi joined the faculty of the University of Texas, MD Anderson Cancer Center as an Associate Professor.  He has a dual appointment in the Departments of Breast Medical Oncology and Melanoma Medical Oncology.

Genesis Biopharma's prestigious SMAB is comprised of leading oncology researchers and clinicians in the U.S., including Cassian Yee, M.D., Professor of Medicine at the University of Washington's Fred Hutchinson Cancer Research Center; James Mule, Ph.D. and Jeffrey Weber, M.D., Ph.D., of the H. Lee Moffitt Cancer Center & Research Institute; Patrick Hwu, M.D. and Laszlo Radvanyi, Ph.D., of MD Anderson Cancer Center; Daniel Powell, Ph.D., of the University of Pennsylvania School of Medicine; Mario Sznol, M.D., of Yale University School of Medicine; and David DiGiusto, Ph.D., of the City of Hope.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing announcement contains forward-looking statements that can be identified by such terminology as "expects", "hopes", "potential", "suggests", "bodes", "may", "should", "could", or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general.  Forward-looking statements speak only as of the date they are made.  The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Genesis Biopharma, Inc.